Clinical trial
Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After…
NCT00125320 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00125320 |
|---|---|
| Title | Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery |
| Official title | A Phase III Study of the Conversion Efficacy and Safety of Repeated Intravenous Doses of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter Following Valvular and/or Coronary Artery Bypass Graft Surgery |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma US, Inc. Industry Advanz Pharma |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation, Atrial Flutter |
| Intervention type | Drug |
| Interventions | RSD1235 |
| Enrollment | 190 |
| Start date | Jun 1, 2004 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Aug 1, 2005 |
| Last update posted | Dec 24, 2007 |
| Countries | Argentina, Canada, Denmark, India, Poland, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: